Back to Search
Start Over
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
- Source :
-
Journal of the National Cancer Institute [J Natl Cancer Inst] 2023 Mar 09; Vol. 115 (3), pp. 332-336. - Publication Year :
- 2023
-
Abstract
- In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29%, and 56%, respectively (P < .001). ERBB2 mRNA was statistically significantly associated with better progression-free survival (P = .002) and overall survival (OS; P = .02). These findings were independent of HER2 immunohistochemistry (IHC) levels, hormone receptor, age, brain metastasis, and line of therapy. The HER2DX risk score (P = .04) and immunoglobulin signature (P = .04) were statistically significantly associated with overall survival since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer.<br /> (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Subjects :
- Humans
Female
Ado-Trastuzumab Emtansine therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Trastuzumab therapeutic use
Receptor, ErbB-2 genetics
Receptor, ErbB-2 metabolism
RNA, Messenger genetics
Breast Neoplasms drug therapy
Breast Neoplasms genetics
Breast Neoplasms metabolism
Maytansine therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1460-2105
- Volume :
- 115
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of the National Cancer Institute
- Publication Type :
- Academic Journal
- Accession number :
- 36576009
- Full Text :
- https://doi.org/10.1093/jnci/djac227